Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730481 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies
A Phase 1 study of Solid Tumor, sponsored by Athenex.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 3
- Study locations
NCT02730481: Completed Phase 1 study of Solid Tumor, sponsored by Athenex.
NCT02730481 is a Phase 1 study of Solid Tumor that has completed, run by Athenex. The registered enrollment target is 38 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02730481, a Phase 1 study of Solid Tumor, has completed, sponsored by Athenex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multicenter, open-label, safety study. Eligible subjects will be adults with advanced malignancies. The study includes a pretreatment and treatment phase. The pretreatment phase consists of screening and baseline periods. The treatment phase consists of 4-week treatment periods and a follow-up period.
Primary Outcome
The highest dose at which no more than 1 of 6 subjects experience a dose-limiting toxicity (DLT) during treatment
Conditions Studied
Interventions
- DRUG Oraxol
Study Locations (3)
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Roswell Park Cancer Institute - Buffalo
Texas
- Cancer Therapy &Research Center @ UTHSCSA - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-03 |
| Est. Completion | 2021-05 |
| Phase | Phase 1 |
What the finished NCT02730481 record still lists
NCT02730481 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Oraxol is the first listed.
NCT02730481 reports a single indexed study location in Massachusetts, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT02730481 about?
NCT02730481 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies". This is a multicenter, open-label, safety study. Eligible subjects will be adults with advanced malignancies. The study includes a pretreatment and treatment phase. The pretreatment phase consists of screening and baseline periods. The treatment phase consists of 4-week treatment periods and a follo...
What is the current status of trial NCT02730481?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2016-03. Estimated completion is 2021-05.
What conditions does trial NCT02730481 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT02730481?
The interventions under investigation include: Oraxol (DRUG).
Who is sponsoring clinical trial NCT02730481?
This trial is sponsored by Athenex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02730481 being conducted?
This trial has 3 study locations across Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02730481's enrollment target sits among peer trials
38 145th of 196 higher than 52 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia